ALS - EuroMOTOR requires the participation of an SME: biotech/pharma (€ 360,000)

The EuroMOTOR consortium has published a competitive call. EuroMOTOR is a European collaborative project dedicated to discover new causative and disease modifying pathways to pave the way for novel therapies for Amyotrophic Lateral Sclerosis. EuroMOTOR has retained a specific budget dedicated to favour the integration of new Small and Medium Enterprises (SME) in the project.

The EuroMOTOR consortium consists of recognized experts in proteomics, metabolomics, genetics, bioinformatics and ALS researchers. Up-to-date cellular and animal models for motor neuron degeneration as well as innovative technology is available and can also be applied to patient samples.

EuroMOTOR aims to strengthen the consortium by including an ambitious SME that can contribute to one and/or combination of the following tasks:
• Identification of the most promising drugable compounds by defining their chemical structure;
• Production of analogues of the compounds; 
• Determination of the structure-activity relationship (SAR) of the compounds.

The call closes on 29 October 2014.